THE BASIC PRINCIPLES OF JOURNAL OF CLINICAL BREAST CANCER

Another bispecific, humanized IgG1 antibody that is under investigation is zenocutuzumab (MCLA-128), which acts through two independent mechanisms of motion: inhibition of HER2–HER3 signalling and elimination of tumour cells via ADCC. MCLA-128 features by using a ‘dock and block’ mechanism whereby a single arm from the antibody binds HER2 are